Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - HC Wainwright issued their Q1 2026 earnings estimates for Protalix BioTherapeutics in a research note issued to investors on Friday, May 23rd. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of $0.09 per share for the quarter. HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Protalix BioTherapeutics' current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics' Q2 2026 earnings at $0.10 EPS, Q3 2026 earnings at $0.12 EPS and Q4 2026 earnings at $0.14 EPS.
Protalix BioTherapeutics (NYSE:PLX - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported ($0.05) earnings per share (EPS) for the quarter. Protalix BioTherapeutics had a negative return on equity of 30.89% and a negative net margin of 21.03%.
Separately, Wall Street Zen lowered shares of Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research report on Monday, May 12th.
Check Out Our Latest Stock Report on PLX
Protalix BioTherapeutics Price Performance
PLX traded up $0.03 during midday trading on Monday, reaching $1.59. 1,159,784 shares of the company's stock were exchanged, compared to its average volume of 544,450. The stock has a market capitalization of $126.58 million, a PE ratio of -12.23 and a beta of -0.05. The business's 50-day moving average price is $2.38 and its 200 day moving average price is $2.19. Protalix BioTherapeutics has a 1-year low of $0.82 and a 1-year high of $3.10.
Hedge Funds Weigh In On Protalix BioTherapeutics
A number of institutional investors have recently modified their holdings of the company. Jane Street Group LLC raised its position in shares of Protalix BioTherapeutics by 159.0% in the first quarter. Jane Street Group LLC now owns 294,318 shares of the company's stock valued at $753,000 after buying an additional 180,702 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Protalix BioTherapeutics by 482.3% in the first quarter. Goldman Sachs Group Inc. now owns 289,461 shares of the company's stock valued at $741,000 after buying an additional 239,751 shares during the last quarter. NewEdge Advisors LLC purchased a new stake in Protalix BioTherapeutics in the first quarter valued at approximately $39,000. Cubist Systematic Strategies LLC grew its holdings in Protalix BioTherapeutics by 82.1% in the first quarter. Cubist Systematic Strategies LLC now owns 53,380 shares of the company's stock valued at $137,000 after purchasing an additional 24,073 shares during the period. Finally, OMERS ADMINISTRATION Corp purchased a new position in Protalix BioTherapeutics during the first quarter worth approximately $459,000. Institutional investors and hedge funds own 16.53% of the company's stock.
Protalix BioTherapeutics Company Profile
(
Get Free Report)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
Featured Articles
Before you consider Protalix BioTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protalix BioTherapeutics wasn't on the list.
While Protalix BioTherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
